---
title: "The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251739486.md"
description: "The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit"
datetime: "2025-08-06T01:52:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251739486.md)
  - [en](https://longbridge.com/en/news/251739486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251739486.md)
generator: "portal-rs"
---

# The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%, and HYBIO, Cosunter, Haisen Pharm, and TY PHAR. also experiencing declines

### Related Stocks

- [002275.CN](https://longbridge.com/en/quote/002275.CN.md)
- [300199.CN](https://longbridge.com/en/quote/300199.CN.md)
- [300436.CN](https://longbridge.com/en/quote/300436.CN.md)
- [001367.CN](https://longbridge.com/en/quote/001367.CN.md)
- [002728.CN](https://longbridge.com/en/quote/002728.CN.md)

## Related News & Research

- [Scott Bessent Brings His Hedge Fund Playbook To Treasury. The Bond Market Is Fighting Back](https://longbridge.com/en/news/296520391.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [TECHNICALS-CBOT wheat may retest support at $6.60-3/4](https://longbridge.com/en/news/296316121.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**